NovaBay Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NBY research report →
About the company
NovaBay Pharmaceuticals, Inc. (NBY) is a pharmaceutical company that specializes in developing and globally distributing products for eyecare and dermatology. Its product portfolio includes Avenova, an advanced solution designed for cleaning the delicate skin around the eye, such as the eyelids, by removing foreign substances, microorganisms, and debris.
- CEO
- Michael Kazley
- IPO
- 2007
- Employees
- 13
- HQ
- EmeryVille, CA, US
Price Chart
- Market Cap
- $39.14M
- P/E
- 0.07
- P/S
- 14.97
- P/B
- 0.25
- EV/EBITDA
- -3.69
- Div Yield
- 294.12%
- Gross Margin
- -3.45%
- Op Margin
- -213.93%
- Net Margin
- 21217.70%
- ROE
- 1715.13%
- ROIC
- -2.96%
- Revenue
- $0 · -100.00%
- Net Income
- $-22,141,000 · -206.53%
- EPS
- $-3.80 · -650.99%
- Op Income
- $-7,585,000
- FCF YoY
- -62.46%
- 52W High
- $99.75
- 52W Low
- $1.11
- 50D MA
- $3.53
- 200D MA
- $9.62
- Beta
- 0.16
- Avg Volume
- 552.07K
Get TickerSpark's AI analysis on NBY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 21, 25 | Lazar David E. | other | 6,388,000 |
| Oct 21, 25 | Lazar David E. | other | 39,925 |
| Oct 21, 25 | Framework Ventures IV L.P. | other | 56,806,080 |
| Oct 16, 25 | Framework Ventures IV L.P. | buy | 2,702,703 |
| Oct 21, 25 | R01 Fund LP | other | 56,806,080 |
| Oct 16, 25 | R01 Fund LP | buy | 2,702,703 |
| Oct 21, 25 | Kazley Michael John | other | 56,806,080 |
| Oct 16, 25 | Kazley Michael John | buy | 2,702,703 |
| Oct 16, 25 | Kazley Michael John | other | 220,663 |
| Oct 16, 25 | Kazley Michael John | other | 134,375 |
Our NBY coverage
Recent articles, reports, and earnings notes.
No research on NBY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NBY report →Similar companies
Peers in the same neighborhood.